<!DOCTYPE html>
<html lang="en">
<head>
<meta name="robots" content="noindex, nofollow">
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<title>CONITEC vs Courts — Judicialização da Saúde</title>
<style>
  :root {
    --bg: #f8f9fa; --card: #fff; --fg: #1a1a1a; --muted: #666;
    --border: #dee2e6; --accent: #0d6efd; --accent2: #198754;
  }
  * { box-sizing: border-box; margin: 0; padding: 0; }
  body {
    font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, sans-serif;
    background: var(--bg); color: var(--fg); line-height: 1.5;
  }

  main {
    padding: 1.5rem 2rem 3rem; max-width: 900px; margin: 0 auto;
  }

  /* Markdown body styles */
  .md-body { font-size: .92rem; line-height: 1.7; color: #1f2328; }

  .md-body h1 { font-size: 1.5rem; font-weight: 600; margin: 1.8rem 0 .8rem; padding-bottom: .3rem; border-bottom: 1px solid var(--border); }
  .md-body h2 { font-size: 1.25rem; font-weight: 600; margin: 1.6rem 0 .6rem; padding-bottom: .25rem; border-bottom: 1px solid var(--border); }
  .md-body h3 { font-size: 1.05rem; font-weight: 600; margin: 1.3rem 0 .5rem; }
  .md-body h4 { font-size: .95rem; font-weight: 600; margin: 1.1rem 0 .4rem; }
  .md-body h5, .md-body h6 { font-size: .88rem; font-weight: 600; margin: 1rem 0 .4rem; }
  .md-body h1:first-child { margin-top: 0; }

  .md-body p { margin: 0 0 .8rem; }

  .md-body ul, .md-body ol { margin: 0 0 .8rem; padding-left: 1.8rem; }
  .md-body li { margin-bottom: .25rem; }
  .md-body li > ul, .md-body li > ol { margin-top: .25rem; margin-bottom: 0; }

  /* Task lists */
  .md-body ul li { list-style: disc; }
  .md-body li input[type="checkbox"] {
    margin-right: .4rem; vertical-align: middle; position: relative; top: -1px;
  }

  .md-body a { color: var(--accent); text-decoration: none; }
  .md-body a:hover { text-decoration: underline; }

  .md-body strong { font-weight: 600; }

  .md-body blockquote {
    margin: 0 0 .8rem; padding: .4rem 1rem;
    border-left: 4px solid var(--accent); background: #f0f4f8;
    color: #555; font-size: .88rem;
  }
  .md-body blockquote p:last-child { margin-bottom: 0; }

  .md-body code {
    font-family: "SFMono-Regular", Consolas, "Liberation Mono", Menlo, monospace;
    font-size: .85em; background: #eef1f5; padding: .15rem .35rem;
    border-radius: 4px;
  }
  .md-body pre {
    margin: 0 0 .8rem; padding: .9rem 1rem;
    background: #f6f8fa; border: 1px solid var(--border);
    border-radius: 6px; overflow-x: auto; line-height: 1.45;
  }
  .md-body pre code {
    background: none; padding: 0; font-size: .82rem;
  }

  .md-body table {
    width: 100%; border-collapse: collapse; margin: 0 0 .8rem;
    font-size: .85rem; display: block; overflow-x: auto;
  }
  .md-body th, .md-body td {
    padding: .45rem .7rem; border: 1px solid var(--border); text-align: left;
  }
  .md-body th { background: #f0f4f8; font-weight: 600; }
  .md-body tr:nth-child(even) td { background: #fafbfc; }

  .md-body hr {
    border: none; border-top: 1px solid var(--border); margin: 1.5rem 0;
  }

  .md-body img { max-width: 100%; }

  /* Collapsible sections */
  .doc-controls { margin-bottom: 1rem; }
  .doc-controls button {
    font-size: .8rem; padding: .3rem .7rem; cursor: pointer;
    background: var(--card); border: 1px solid var(--border); border-radius: 4px;
    color: var(--accent); font-weight: 600;
  }
  .doc-controls button:hover { background: #e7f1ff; }
  .md-body details { margin-bottom: .5rem; }
  .md-body details summary {
    font-weight: 600; cursor: pointer; list-style: none;
  }
  .md-body details summary::-webkit-details-marker { display: none; }
  .md-body details summary::before {
    content: "\25b6"; font-size: .7em; margin-right: .5rem;
    display: inline-block; transition: transform .15s;
  }
  .md-body details[open] summary::before { transform: rotate(90deg); }
  .md-body details.level-2 > summary {
    font-size: 1.25rem; padding-bottom: .25rem;
    border-bottom: 1px solid var(--border); margin: 1.6rem 0 .6rem;
  }
  .md-body details.level-3 > summary {
    font-size: 1.05rem; margin: 1.3rem 0 .5rem;
  }

  footer {
    text-align: center; padding: 1.5rem; font-size: .8rem; color: var(--muted);
    border-top: 1px solid var(--border); margin-top: 2rem;
  }
</style>
</head>
<body>

<style>
  .site-nav {
    position: sticky; top: 0; z-index: 100;
    background: #212529; display: flex; align-items: center;
    padding: 0 2rem; height: 3rem;
  }
  .site-nav .nav-brand {
    color: #fff; text-decoration: none; font-weight: 600; font-size: 1rem;
    margin-right: auto;
  }
  .site-nav .nav-brand:hover { color: #e9ecef; }
  .site-nav .nav-link {
    color: #adb5bd; text-decoration: none; font-size: .85rem;
    padding: 0 .75rem; height: 3rem; display: flex; align-items: center;
    background: none; border: none; cursor: pointer; font-family: inherit;
  }
  .site-nav .nav-link:hover, .site-nav .nav-link.active { color: #fff; }
  .nav-dropdown { position: relative; }
  .dropdown-menu {
    display: none; position: absolute; top: 3rem; right: 0;
    background: #fff; border: 1px solid var(--border); border-radius: 6px;
    box-shadow: 0 4px 16px rgba(0,0,0,.12); min-width: 220px;
    padding: .4rem 0; z-index: 200; max-height: 80vh; overflow-y: auto;
  }
  .nav-dropdown.open .dropdown-menu { display: block; }
  .dropdown-menu a {
    display: block; padding: .3rem 1rem; color: #1a1a1a;
    text-decoration: none; font-size: .82rem;
  }
  .dropdown-menu a:hover { background: #f0f4f8; }
  .dropdown-group-label {
    padding: .4rem 1rem .15rem; font-size: .68rem; font-weight: 700;
    color: #888; text-transform: uppercase; letter-spacing: .04em;
  }
  .dropdown-divider { border-top: 1px solid #eee; margin: .3rem 0; }
  .page-header {
    padding: .8rem 2rem; border-bottom: 1px solid var(--border); background: #fff;
  }
  .page-header h1 { font-size: 1.3rem; font-weight: 600; }
  .page-header p { color: var(--muted); font-size: .85rem; margin-top: .15rem; }
</style>

<nav class="site-nav">
  <a href="../index.html" class="nav-brand">Judicialização da Saúde</a>
  <a href="../paper/index.html" class="nav-link">Paper</a>
  <div class="nav-dropdown">
    <button class="nav-link active">Docs &#9662;</button>
    <div class="dropdown-menu">
    <div class="dropdown-group-label">Research reference</div>
    <a href="../docs/README.html">Project Overview</a>
    <a href="../docs/summary.html">Research Summary</a>
    <a href="../docs/institutions.html">Institutional Background</a>
    <a href="../docs/data.html">Data Sources</a>
    <a href="../docs/methods.html">Empirical Methods</a>
    <a href="../docs/literature.html">Literature</a>
    <a href="../docs/theory.html">Theoretical Framework</a>
    <a href="../docs/hypotheses.html">Hypotheses & Evidence</a>
    <div class="dropdown-divider"></div>
    <div class="dropdown-group-label">Working notes</div>
    <a href="../docs/thinking.html">Open Questions & Ideas</a>
    <a href="../docs/decisions.html">Key Decisions</a>
    <a href="../docs/qa.html">Research Q&A</a>
    <div class="dropdown-divider"></div>
    <div class="dropdown-group-label">Task tracking</div>
    <a href="../docs/todo.html">Active Tasks</a>
    <a href="../docs/done.html">Completed Tasks</a>
    <div class="dropdown-divider"></div>
    <div class="dropdown-group-label">Communication</div>
    <a href="../docs/meetings.html">Meeting Notes</a>
    <a href="../docs/feedback.html">External Feedback</a>
    <div class="dropdown-divider"></div>
    <div class="dropdown-group-label">Court analysis</div>
    <a href="../docs/01-stf-reasoning-templates.html">STF Reasoning Templates</a>
    <a href="../docs/02-stj-repetitivos-patterns.html">STJ Repetitivos Patterns</a>
    <a href="../docs/03-tjsp-plans-vs-sus.html">TJSP: Plans vs SUS</a>
    <a href="../docs/04-conitec-pcdt-vs-courts.html">CONITEC vs Courts</a>
    <a href="../docs/05-interfederative-responsibility.html">Interfederative Responsibility</a>
    </div>
  </div>
  <div class="nav-dropdown">
    <button class="nav-link">Data &#9662;</button>
    <div class="dropdown-menu">
    <a href="../sources/tjsp.html">TJSP</a>
    <a href="../sources/datajud.html">DataJud</a>
    <a href="../sources/stf-stj.html">STF & STJ</a>
    <a href="../sources/trf3.html">TRF3</a>
    <a href="../sources/spending.html">Municipal Spending</a>
    <a href="../sources/legislation.html">Health Legislation</a>
    </div>
  </div>
  <a href="../references/index.html" class="nav-link">References</a>
  <a href="../news/index.html" class="nav-link">News</a>
</nav>
<script>
document.querySelectorAll('.nav-dropdown > .nav-link').forEach(function(btn) {
  btn.addEventListener('click', function(e) {
    e.stopPropagation();
    var dd = btn.parentElement;
    var wasOpen = dd.classList.contains('open');
    document.querySelectorAll('.nav-dropdown.open').forEach(function(d) { d.classList.remove('open'); });
    if (!wasOpen) dd.classList.add('open');
  });
});
document.addEventListener('click', function() {
  document.querySelectorAll('.nav-dropdown.open').forEach(function(d) { d.classList.remove('open'); });
});
</script>

<div class="page-header">
  <h1>CONITEC vs Courts</h1>
</div>

<main>
<div class="doc-controls">
  <button id="toggle-sections">Expand all</button>
</div>
<div class="md-body">
<h1>CONITEC/PCDT vs Court Orders: Recurring Points of Conflict</h1>
<h2 id="overview">Overview</h2>
<p>This memo analyzes the systematic tensions between health technology assessment (CONITEC decisions, PCDT protocols) and judicial orders. Understanding these conflicts is essential for predicting litigation patterns and outcomes.</p>
<hr />
<h2 id="1-the-institutional-framework">1. The Institutional Framework</h2>
<h3 id="conitec-comiss-o-nacional-de-incorpora-o-de-tecnologias-no-sus">CONITEC (Comissão Nacional de Incorporação de Tecnologias no SUS)</h3>
<p><strong>Role:</strong> Evaluates whether medications, procedures, and health products should be incorporated into SUS.</p>
<p><strong>Process:</strong></p>
<ol>
<li>Submission (manufacturer, society, ministry)</li>
<li>Technical analysis (efficacy, safety, cost-effectiveness)</li>
<li>Public consultation</li>
<li>Plenary deliberation</li>
<li>Ministry of Health decision</li>
<li>If positive → incorporation → RENAME/PCDT update</li>
</ol>
<p><strong>Criteria:</strong></p>
<ul>
<li>Clinical efficacy (evidence-based)</li>
<li>Safety profile</li>
<li>Cost-effectiveness (ICER thresholds)</li>
<li>Budget impact</li>
<li>Equity considerations</li>
</ul>
<h3 id="pcdts-protocolos-cl-nicos-e-diretrizes-terap-uticas">PCDTs (Protocolos Clínicos e Diretrizes Terapêuticas)</h3>
<p><strong>Role:</strong> Define standard treatment pathways for conditions covered by SUS.</p>
<p><strong>Content:</strong></p>
<ul>
<li>Diagnostic criteria</li>
<li>Treatment lines (first-line, second-line, etc.)</li>
<li>Dosing and duration</li>
<li>Monitoring requirements</li>
<li>Exclusion criteria</li>
</ul>
<hr />
<h2 id="2-core-conflicts">2. Core Conflicts</h2>
<h3 id="2-1-the-evidence-gap">2.1 The Evidence Gap</h3>
<p><strong>CONITEC perspective:</strong></p>
<blockquote>
<p>&quot;The evidence does not demonstrate superiority over existing treatments to justify the additional cost.&quot;</p>
</blockquote>
<p><strong>Judicial perspective:</strong></p>
<blockquote>
<p>&quot;The treating physician prescribed it; the prescription demonstrates medical necessity.&quot;</p>
</blockquote>
<p><strong>Conflict:</strong> Courts often accept individual prescriptions as sufficient evidence, while CONITEC requires population-level evidence of comparative effectiveness.</p>
<h3 id="2-2-cost-effectiveness-threshold">2.2 Cost-Effectiveness Threshold</h3>
<p><strong>CONITEC applies thresholds:</strong></p>
<ul>
<li>Implicit ICER threshold: ~1-3x GDP per capita per QALY</li>
<li>Budget impact analysis for affordability</li>
</ul>
<p><strong>Courts generally don't consider:</strong></p>
<ul>
<li>Cost-effectiveness ratios</li>
<li>Opportunity costs (what won't be funded if this is)</li>
<li>System-wide budget impacts</li>
</ul>
<p><strong>Typical judicial reasoning:</strong></p>
<blockquote>
<p>&quot;O direito à saúde não pode ser condicionado a critérios econômicos quando a vida está em risco.&quot;</p>
</blockquote>
<h3 id="2-3-timeline-mismatch">2.3 Timeline Mismatch</h3>
<table>
<thead>
<tr>
  <th>CONITEC Process</th>
  <th>Judicial Process</th>
</tr>
</thead>
<tbody>
<tr>
  <td>180 days (standard)</td>
  <td>Days to weeks (tutela urgência)</td>
</tr>
<tr>
  <td>Up to 360 days (complex)</td>
  <td>Immediate if emergency</td>
</tr>
</tbody>
</table>
<p><strong>Conflict:</strong> Patients litigate while CONITEC is still evaluating, or before CONITEC even receives submission.</p>
<h3 id="2-4-individual-vs-population">2.4 Individual vs Population</h3>
<p><strong>CONITEC:</strong> Makes population-level decisions</p>
<ul>
<li>&quot;On average, this drug doesn't improve outcomes enough&quot;</li>
<li>&quot;For most patients, the existing treatment is adequate&quot;</li>
</ul>
<p><strong>Courts:</strong> Decide individual cases</p>
<ul>
<li>&quot;THIS patient's doctor says they need THIS drug&quot;</li>
<li>&quot;THIS patient didn't respond to standard treatment&quot;</li>
</ul>
<hr />
<h2 id="3-the-quot-conitec-rejected-quot-problem">3. The &quot;CONITEC Rejected&quot; Problem</h2>
<h3 id="when-conitec-says-quot-no-quot">When CONITEC Says &quot;No&quot;</h3>
<p><strong>Three scenarios:</strong></p>
<ol>
<li><p><strong>Not submitted:</strong> CONITEC never evaluated</p>
<ul>
<li>Courts more willing to grant (Tema 6 may apply)</li>
</ul>
</li>
<li><p><strong>Rejected:</strong> CONITEC evaluated and recommended against</p>
<ul>
<li>Post-Tema 6: Strong deference expected</li>
<li>But courts sometimes still grant if &quot;individual circumstances&quot;</li>
</ul>
</li>
<li><p><strong>Incorporated with restrictions:</strong> CONITEC said yes, but only for specific indications</p>
<ul>
<li>Courts may expand to other indications (off-label)</li>
</ul>
</li>
</ol>
<h3 id="judicial-responses-to-conitec-rejection">Judicial Responses to CONITEC Rejection</h3>
<p><strong>Deferential response:</strong></p>
<blockquote>
<p>&quot;A CONITEC, órgão técnico competente, avaliou a tecnologia e não recomendou sua incorporação. O Judiciário não pode substituir-se ao administrador na definição de políticas públicas de saúde.&quot;</p>
</blockquote>
<p><strong>Non-deferential response:</strong></p>
<blockquote>
<p>&quot;A decisão da CONITEC não vincula o Judiciário quando demonstrada, no caso concreto, a necessidade individual do tratamento e a ineficácia das alternativas terapêuticas.&quot;</p>
</blockquote>
<hr />
<h2 id="4-pcdt-conflicts-in-practice">4. PCDT Conflicts in Practice</h2>
<h3 id="4-1-line-of-treatment-disputes">4.1 Line of Treatment Disputes</h3>
<p><strong>PCDT says:</strong></p>
<blockquote>
<p>&quot;First-line: Drug A. Second-line (if A fails): Drug B. Third-line: Drug C.&quot;</p>
</blockquote>
<p><strong>Patient wants:</strong></p>
<blockquote>
<p>&quot;Drug C immediately, without trying A and B.&quot;</p>
</blockquote>
<p><strong>Court response (typical):</strong></p>
<blockquote>
<p>If physician documents why A and B aren't appropriate for this patient, court may grant C directly.</p>
</blockquote>
<h3 id="4-2-diagnostic-criteria-disputes">4.2 Diagnostic Criteria Disputes</h3>
<p><strong>PCDT says:</strong></p>
<blockquote>
<p>&quot;Eligible patients must have [specific lab values, symptoms, etc.]&quot;</p>
</blockquote>
<p><strong>Patient presents:</strong></p>
<blockquote>
<p>Borderline criteria, or criteria met by different methodology</p>
</blockquote>
<p><strong>Conflict:</strong> Is the patient &quot;in&quot; or &quot;out&quot; of PCDT coverage?</p>
<h3 id="4-3-duration-and-dosing">4.3 Duration and Dosing</h3>
<p><strong>PCDT says:</strong></p>
<blockquote>
<p>&quot;Maximum duration: 12 months&quot; or &quot;Maximum dose: X mg&quot;</p>
</blockquote>
<p><strong>Physician prescribes:</strong></p>
<blockquote>
<p>Continuation beyond 12 months, or higher dose</p>
</blockquote>
<p><strong>Courts:</strong> Often grant if physician justifies clinical need.</p>
<hr />
<h2 id="5-the-quot-therapeutic-substitute-quot-battlefield">5. The &quot;Therapeutic Substitute&quot; Battlefield</h2>
<h3 id="key-tema-6-requirement">Key Tema 6 Requirement</h3>
<blockquote>
<p>Plaintiff must show &quot;inexistência de substituto terapêutico incorporado pelo SUS&quot;</p>
</blockquote>
<h3 id="what-counts-as-a-quot-substitute-quot">What Counts as a &quot;Substitute&quot;?</h3>
<p><strong>Strict view:</strong></p>
<blockquote>
<p>Any drug in the same therapeutic class that treats the condition.</p>
</blockquote>
<p><strong>Narrow view:</strong></p>
<blockquote>
<p>Only a drug with equivalent efficacy and tolerability for THIS patient.</p>
</blockquote>
<p><strong>Courts increasingly adopt narrow view:</strong></p>
<blockquote>
<p>&quot;Não basta a existência de medicamento da mesma classe terapêutica; é necessário que seja efetivamente equivalente para o paciente.&quot;</p>
</blockquote>
<h3 id="common-disputes">Common Disputes</h3>
<table>
<thead>
<tr>
  <th>Requested Drug</th>
  <th>SUS Offers</th>
  <th>Court Often Says</th>
</tr>
</thead>
<tbody>
<tr>
  <td>Brand-name</td>
  <td>Generic</td>
  <td>Generic is equivalent → Deny</td>
</tr>
<tr>
  <td>Newer biologic</td>
  <td>Older biologic</td>
  <td>May grant if documented failure on older</td>
</tr>
<tr>
  <td>Oral formulation</td>
  <td>Injectable</td>
  <td>May grant for compliance/convenience</td>
</tr>
<tr>
  <td>Combination drug</td>
  <td>Separate drugs</td>
  <td>Usually deny (same effect)</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="6-the-quot-evidence-based-medicine-quot-standard">6. The &quot;Evidence-Based Medicine&quot; Standard</h2>
<h3 id="tema-6-requirement">Tema 6 Requirement</h3>
<blockquote>
<p>&quot;Comprovação de eficácia do medicamento à luz da medicina baseada em evidências&quot;</p>
</blockquote>
<h3 id="what-evidence-courts-accept">What Evidence Courts Accept</h3>
<p><strong>Strong evidence (usually sufficient):</strong></p>
<ul>
<li>ANVISA registration for the indication</li>
<li>Randomized controlled trials</li>
<li>Meta-analyses/systematic reviews</li>
<li>International guideline recommendations</li>
</ul>
<p><strong>Weaker evidence (contested):</strong></p>
<ul>
<li>Case series</li>
<li>Expert opinion letters</li>
<li>Off-label use without trials</li>
<li>Foreign approvals without Brazilian registration</li>
</ul>
<h3 id="the-quot-anvisa-registered-quot-shortcut">The &quot;ANVISA Registered&quot; Shortcut</h3>
<p><strong>Common judicial reasoning:</strong></p>
<blockquote>
<p>&quot;O medicamento possui registro na ANVISA, o que atesta sua segurança e eficácia.&quot;</p>
</blockquote>
<p><strong>Problem:</strong> ANVISA registration ≠ CONITEC incorporation</p>
<ul>
<li>ANVISA: Is it safe and effective? (Yes/No)</li>
<li>CONITEC: Is it worth the cost vs. alternatives? (Comparative)</li>
</ul>
<hr />
<h2 id="7-recurring-case-types">7. Recurring Case Types</h2>
<h3 id="7-1-oncology">7.1 Oncology</h3>
<p><strong>CONITEC challenge:</strong></p>
<ul>
<li>New drugs are expensive (R$20-50k/month)</li>
<li>Evidence often from single-arm trials</li>
<li>Multiple indications requested rapidly</li>
</ul>
<p><strong>Court tendency:</strong></p>
<ul>
<li>High grant rate for cancer drugs</li>
<li>&quot;Risco de vida&quot; argument is compelling</li>
<li>Less scrutiny of cost-effectiveness</li>
</ul>
<p><strong>Typical drugs:</strong> Pembrolizumabe, Nivolumabe, targeted therapies</p>
<h3 id="7-2-rare-diseases">7.2 Rare Diseases</h3>
<p><strong>CONITEC challenge:</strong></p>
<ul>
<li>Small patient populations</li>
<li>Limited evidence (rare disease = rare data)</li>
<li>Extremely high costs (R$50-150k/month)</li>
</ul>
<p><strong>Court tendency:</strong></p>
<ul>
<li>High grant rate</li>
<li>&quot;No alternative&quot; argument works well</li>
<li>Less emphasis on evidence quality</li>
</ul>
<p><strong>Typical drugs:</strong> Enzyme replacement therapies, gene therapies</p>
<h3 id="7-3-autoimmune-inflammatory">7.3 Autoimmune/Inflammatory</h3>
<p><strong>CONITEC position:</strong></p>
<ul>
<li>Many biologics incorporated</li>
<li>Specific indications defined in PCDTs</li>
<li>Step therapy required</li>
</ul>
<p><strong>Court tendency:</strong></p>
<ul>
<li>Grant when step therapy documented as failed</li>
<li>Grant for off-label indications with evidence</li>
<li>Moderate scrutiny</li>
</ul>
<p><strong>Typical drugs:</strong> Adalimumabe, Infliximabe, Secuquinumabe</p>
<h3 id="7-4-mental-health">7.4 Mental Health</h3>
<p><strong>CONITEC gap:</strong></p>
<ul>
<li>Fewer mental health drugs evaluated</li>
<li>PCDTs less comprehensive</li>
</ul>
<p><strong>Court tendency:</strong></p>
<ul>
<li>Variable outcomes</li>
<li>Increasing litigation for newer antipsychotics, ketamine, cannabis</li>
</ul>
<hr />
<h2 id="8-post-2024-changes-svs-60-61">8. Post-2024 Changes (SVs 60-61)</h2>
<h3 id="expected-impact-on-conflicts">Expected Impact on Conflicts</h3>
<p><strong>Before:</strong></p>
<ul>
<li>Courts freely substituted CONITEC judgment</li>
<li>Administrative path often bypassed</li>
<li>NAT-Jus consultation optional</li>
</ul>
<p><strong>After:</strong></p>
<ul>
<li>Stronger deference to CONITEC expected</li>
<li>Administrative exhaustion required (SV 60)</li>
<li>NAT-Jus consultation institutionalized</li>
<li>Interfederative agreements structure process</li>
</ul>
<h3 id="remaining-gaps">Remaining Gaps</h3>
<p>Even post-2024, conflicts persist when:</p>
<ul>
<li>CONITEC hasn't evaluated the drug yet</li>
<li>Patient is &quot;different&quot; from PCDT population</li>
<li>New evidence emerges after CONITEC decision</li>
<li>Off-label use for rare situations</li>
</ul>
<hr />
<h2 id="9-strategic-implications">9. Strategic Implications</h2>
<h3 id="for-plaintiffs-patients">For Plaintiffs (Patients)</h3>
<p><strong>Stronger cases:</strong></p>
<ul>
<li>CONITEC hasn't evaluated (not rejected)</li>
<li>Documented failure on PCDT alternatives</li>
<li>Life-threatening condition</li>
<li>Strong evidence (trials, guidelines)</li>
</ul>
<p><strong>Weaker cases:</strong></p>
<ul>
<li>CONITEC explicitly rejected</li>
<li>Haven't tried PCDT alternatives</li>
<li>Convenience/preference-based</li>
<li>Weak evidence (anecdotes, case reports)</li>
</ul>
<h3 id="for-state-defense">For State Defense</h3>
<p><strong>Stronger defenses:</strong></p>
<ul>
<li>CONITEC evaluated and rejected with reasons</li>
<li>Effective substitute available in PCDT</li>
<li>Plaintiff hasn't tried standard treatment</li>
<li>Evidence doesn't support superiority</li>
</ul>
<p><strong>Weaker defenses:</strong></p>
<ul>
<li>&quot;Budget constraints&quot; alone</li>
<li>&quot;Not incorporated&quot; without explaining why</li>
<li>PCDT exists but patient clearly outside criteria</li>
</ul>
<hr />
<h2 id="10-data-cross-references">10. Data Cross-References</h2>
<h3 id="most-litigated-drugs-by-conitec-status">Most Litigated Drugs by CONITEC Status</h3>
<p>See: <code>data/mapeamento_medicamentos_judicializados.csv</code></p>
<table>
<thead>
<tr>
  <th>CONITEC Status</th>
  <th>Litigation Level</th>
</tr>
</thead>
<tbody>
<tr>
  <td>Not evaluated</td>
  <td>Very High</td>
</tr>
<tr>
  <td>Rejected</td>
  <td>High (despite Tema 6)</td>
</tr>
<tr>
  <td>Incorporated with restrictions</td>
  <td>Medium</td>
</tr>
<tr>
  <td>Fully incorporated</td>
  <td>Low</td>
</tr>
</tbody>
</table>
<h3 id="conitec-decisions-database">CONITEC Decisions Database</h3>
<p>See: <code>data/conitec/recomendacoes-conitec-2026.xlsx</code></p>
<ul>
<li>745 medication evaluations</li>
<li>~45% incorporated</li>
<li>~29% not incorporated</li>
<li>Remainder: protocols, procedures, updates</li>
</ul>
<hr />
<h2 id="key-documents-to-cross-reference">Key Documents to Cross-Reference</h2>
<ul>
<li><code>data/conitec/recomendacoes-conitec-2026.xlsx</code> - All CONITEC decisions</li>
<li><code>data/rename/rename-2024.pdf</code> - What IS incorporated</li>
<li><code>data/pcdts/pcdts-volume3-2014.pdf</code> - Example PCDT structure</li>
<li><code>data/mapeamento_medicamentos_judicializados.csv</code> - Drug-level mapping</li>
<li><code>data/stf_teses/sumulas-vinculantes-60-61-saude.txt</code> - Current framework</li>
</ul>

</div>
</main>

<footer>
  Generated by <code>bash build.sh site</code>
</footer>

<script>
document.addEventListener('DOMContentLoaded', () => {
  const body = document.querySelector('.md-body');
  if (!body) return;

  function foldHeadings(container, tag) {
    const level = tag.replace('H', '');
    const headings = Array.from(container.querySelectorAll(':scope > ' + tag.toLowerCase()));
    headings.forEach(h => {
      const details = document.createElement('details');
      details.className = 'level-' + level;
      if (h.id) details.id = h.id;
      const summary = document.createElement('summary');
      summary.innerHTML = h.innerHTML;
      details.appendChild(summary);
      let sibling = h.nextElementSibling;
      const collected = [];
      while (sibling && sibling.tagName !== tag) {
        collected.push(sibling);
        sibling = sibling.nextElementSibling;
      }
      collected.forEach(el => details.appendChild(el));
      h.replaceWith(details);
    });
    return headings.length;
  }

  // Fold h2 sections, then h3 sections within each h2
  const count = foldHeadings(body, 'H2');
  if (count === 0) {
    document.querySelector('.doc-controls').style.display = 'none';
    return;
  }
  body.querySelectorAll('details.level-2').forEach(d => foldHeadings(d, 'H3'));

  // Toggle button
  const btn = document.getElementById('toggle-sections');
  if (!btn) return;
  btn.addEventListener('click', () => {
    const allDetails = body.querySelectorAll('details');
    const expanding = btn.textContent === 'Expand all';
    allDetails.forEach(d => d.open = expanding);
    btn.textContent = expanding ? 'Collapse all' : 'Expand all';
  });

  // Auto-open details when navigating to an anchor
  function openAnchorTarget() {
    if (!location.hash) return;
    const target = document.querySelector(location.hash);
    if (!target) return;
    let el = target;
    while (el) {
      if (el.tagName === 'DETAILS') el.open = true;
      el = el.parentElement;
    }
    target.scrollIntoView();
  }
  openAnchorTarget();
  window.addEventListener('hashchange', openAnchorTarget);
});
</script>

</body>
</html>
